Evidence map›Paper›PMID 31792639›Full record

ArticleClinical and experimental nephrology2020

Preventive effect of early introduction of everolimus and reduced-exposure tacrolimus on renal interstitial fibrosis in de novo living-donor renal transplant recipients.

Hiroaki Ishida, Go Ogura, Saeko Uehara, Shinya Takiguchi, Yousuke Nakagawa, Naoto Hamano, Masahiro Koizumi, Takehiko Wada, Masafumi Fukagawa, Michio Nakamura

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hiroaki IshidaDepartment of Transplant Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Go OguraDepartment of Pathology, Tokai University School of Medicine, Shimokasuya, Isehara, Japan.
Saeko UeharaDepartment of Transplant Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Shinya TakiguchiDepartment of Transplant Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Yousuke NakagawaDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Shimokasuya, Isehara, Japan.
Naoto HamanoDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Shimokasuya, Isehara, Japan.
Masahiro KoizumiDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Shimokasuya, Isehara, Japan.
Takehiko WadaDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Shimokasuya, Isehara, Japan.
Masafumi FukagawaDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Shimokasuya, Isehara, Japan.
Michio NakamuraDepartment of Transplant Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. mnakamura@tokai-u.jp.ORCID http://orcid.org/0000-0002-6606-1872
Tokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo improve the long-term outcomes following renal transplantation, prevention of renal-allograft interstitial fibrosis (IF), mainly due to calcineurin inhibitors, is an important therapeutic target. Everolimus (EVR) was reported to have antifibrotic effects. We aimed to investigate the safety, efficacy, and IF of our modified immunosuppressive regimen, which includes early introduction of EVR and reduced-exposure tacrolimus (Tac) (EVR group), and compare it with the standard-exposure tacrolimus-based regimen (Tac group) in de novo living-donor renal recipients.

methodsIn this retrospective, single-center cohort study, we compared the 2-year clinical courses between the two groups according to intention to treat. Additionally, in patients in whom biopsies were obtained at 1 h, 3 months, and 12 months post-transplant, we compared IF between the groups using imaging analysis.

resultsOverall, 47 patients were included (EVR group, n = 22; Tac group, n = 25). There were no significant differences in renal function and incidences of rejection and viral infections between the groups at the 2-year post-transplant follow-up. However, pathologic imaging analysis (n = 34) revealed chronological progression of IF in the Tac group during the first year post-transplant and no changes in the EVR group (fibrosis rate at 3 months: 20.8 vs. 13.6%, p < 0.001; at 12 months: 24.7 vs. 14.7%, p < 0.001, respectively).

conclusionOur modified immunosuppressive regimen may have an antifibrotic effect on transplanted kidneys without loss of safety and efficacy.

Indexed as

Kidney TransplantationAdultEverolimusFemaleFibrosisHumansImmunosuppressive AgentsKidneyLiving DonorsMaleMiddle AgedPostoperative ComplicationsRetrospective StudiesTacrolimusEverolimusImmunosuppressive AgentsTacrolimusEverolimusInterstitial fibrosisMammalian target of rapamycin inhibitorRenal transplantationTacrolimus

Identifiers

PMID31792639
OpenAlexW4248568434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.